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Int J Infect Dis 2002; 6: 326-328 
A 50-year-old man presenting with blast transformation 
of Philadephia chromosome positive chronic myelocytic 
leukemia was admitted to receive chemotherapy with 
idarubicin, cytosine arabinoside, and etoposid. Previous 
treatments consisted of hydroxycarbamide and mitox- 
antrone. 
Physical examination disclosed a systolic cardiac 
murmur and hepatosplenomegaly. A right subclavian 
implantable central venous access device was in place. 
Prophylactic treatment was initiated with oral cipro- 
floxacin 500 mg twice daily, and fluconazole, 200 mg 
once daily. From day 3 to day 9, the patient’s tempera- 
ture peaked in the evening, ascribed to cytosine arabi- 
noside and tumor lysis with a decrease of the spleen’s 
volume. At day 10, the patient became neutropenic 
while still febrile with a C-reactive protein (CRP) of 7.3 
mg/dL (normal value < 1 mg/dL). He received 
piperacillin-tazobactam 4 g four times a day. On day 11, 
empirical teicoplanin was added because a temperature 
of 38.5”C associated with skin redness at the central 
venous implantation site. From day 12 to day 19, the 
patient remained afebrile, his spleen continued to 
decrease in volume and the CRP decreased. 
On day 20, the patient’s temperature was 39°C with 
rigors. The CRP level rose from 0.9 mg/dL to 6.2 mg/dL. 
The antibacterial prophylactic treatment was stopped 
and the patient received amikacin 1 g per day intra- 
venously and imipenem-cilastatin 500 mg three times a 
day. Swabs revealed intestinal and pharyngeal coloniz- 
ation by Candida krusei. On day 22, erythematous 
macules and papules less than 1 cm in diameter 
appeared on the thorax, the abdomen, and the limbs. A 
skin biopsy was performed: direct examination revealed 
the presence of yeast. Previous treatment was stopped, 
amphotericin B and meropenem were started. Blood 
cultures performed on day 20 were positive for C. 
krusei. An examination of the fundi showed a septic 
embolus. 
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From day 23 to day 26, the patient’s state worsened. 
He experienced transitory myalgia in his calves, and the 
skin lesions increased in size and number. Temperature 
remained above 39°C and fine crepitant rales were 
audible at the lung bases. Blood culture remained posi- 
tive for C. krusei. The skin biopsy culture was positive 
for C. krusei. Flucytosine 100 mglkg per day intra- 
venously was started on day 24 but stopped on day 
26 because of the in vitro resistance of this C. krusei 
strain. 
In the absence of clinical and biologic response to 
the treatment, the central venous catheter was removed 
on day 26 (a smear of catheter culture was positive for 
C. krusei), granulocyte colony-stimulating factor (G- 
CSF) was administered (480 ug/d in subcutaneous injec- 
tion) and amphotericin B lipid complex (ABLC), 5 
mg/kg per day intravenously, replaced conventional 
amphotericin B. 
On day 27, the patient became afebrile and his gen- 
eral state progressively improved. Skin lesions signifi- 
cantly regressed in number and size. Blood cultures 
became negative. Throat colonization by C. krusei per- 
sisted. The patient’s neutropenia resolved on day 28, 
and CRP level decreased. Examination of the fundi 
showed resolution of the septic embolus on day 33. The 
G-CSF was stopped on day 30, meropenem on day 31 
and ABLC on day 39. (Conventional amphotericin B 
was given for 4 days and ABLC for 13 days; total cumu- 
lative dose of amphotericin B was 3.45 g.) The patient 
was able to leave the hospital the following week. 
Candida krusei is increasingly frequent in dissemi- 
nated candidiasis, which is the most frequent fungal 
infection in cancer patients.l-lo The use of high-dose 
chemotherapy, wide-spectrum antibiotics, organ trans- 
plants, long-term therapy with steroids, and central 
venous catheters would be partially responsible for that 
increase.2,9-16 
The risk factors for invasive C. krusei candidiasis 
are neutropenia, lesions of the gastrointestinal barrier, 
and colonization. If C. krusei is isolated from a control 
culture, the patient must be followed closely and an 
empirical treatment must be started as soon as a fungal 
infection is suspected.2J2J7 
According to Goldman and colleagues, overall 
mortality from C. krusei fungemia is 48%, varying 
between 100% in the absence of treatment to 44% 
when treated, the difference being statistically signifi- 
cant on the 62 cases reported.’ Meunier et al reported a 
41.8% mortality rate in cases of Candida (all species) 
fungemia, ranging from 53.4% for C. albicans to 16.6% 
for C. tropicalis or C. krusei.12 When the central venous 
catheter is removed, the consequences and the mor- 
tality rate of a C. krusei fungemia decrease.2,18,19 Flu- 
conazole is ineffective in the eradication of disseminated 
C. krusei.20 Standard therapy in cases of C. krusei 
fungemia should be amphotericin B with the removal 
of the catheter.2~9~10~21~22 C an I a d’d k rusei is less sensitive 
to amphotericin B in vitro than C. al&cans, and the clin- 
ical response to amphotericin B is better at doses 
higher than 1 mg/kg/per day.1,22,2” 
The amount of amphotericin B administered is 
limited by the therapeutic index. Lipid formulations 
allow patients to receive higher doses for longer periods 
of time with decreased renal toxicity than with conven- 
tional amphotericin B. 
The currently approved dose for ABLC is 5 mg/kg 
administered at a rate of 2.5 mg/kg per hour.24 
Amphotericin B lipid complex demonstrates less 
nephrotoxicity and produces a less marked deterior- 
ation in glomerular filtration rate than amphotericin B. 
Walsh and colleagues observed a significant decrease of 
serum creatinine during ABLC treatment among 556 
cases of invasive fungal infection in patients refractory 
to or intolerant of amphotericin B. Infusion-related 
reactions occur with decreased frequency relative to 
amphotericin B : fever and chills were reported in 
15.8% of cases treated with amphotericin B and in 
8.8% of cases treated with ABLC. Nevertheless, life- 
threatening adverse events can be associated with the 
use of ABLC in cases in which amphotericin B deoxy- 
cholate has been administered without event. Respira- 
tory distress is a relatively uncommon but known 
complication associated with use of ABLC.24-26 
Amphotericin B lipid complex has been approved 
by the American Food and Drug Administration for the 
treatment of invasive fungal infections in patients 
who are refractory to or intolerant of amphotericin B. 
Increasing serum creatinine in a patient with a serious 
fungal infection should result in a consideration to 
change from amphotericin B to ABLC.24-26 
Different studies have reported ABLC to have 
a clinical response of 78% in candidiasis, 67% in 
disseminated candidiasis, 63% in hematogenous and 
invasive candidiasis.24.27 
There are no adequate data showing that ABLC is 
superior to conventional amphotericin B in recovery 
rates. The only published randomized study in which 
the two formulations were compared concluded that 
ABLC (5 mg/kg/d) is as effective as conventional 
amphotericin B (2.5 mg/kg/d) in the treatment of hema- 
togenous and invasive candidiasis (overall response rate 
of 65% compared with 61%, no significant difference). 
Additional randomized studies are needed to define the 
role of ABLC as first-line therapy.28-30 
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However the following guidelines for use of ABLC 
have been proposed: pre-existing renal insufficiency, 
high risk of nephrotoxicity, nephrotoxicity from ampho- 
tericin B, and documented fungal infections that do not 
improve following treatment with a cumulative dose of 
amphotericin B (>7 mg/kg).30 
Candida krusei is an increasingly frequent patho- 
gen among immunocompromised patients, especially 
those undergoing highly myoablative chemotherapy for 
hematologic malignancies. Early diagnosis is essential, 
skin lesions and ophthalmic signs can be of great diag- 
nostic value. 
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